|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||60.72 - 61.94|
|52 Week Range||42.11 - 63.09|
|Beta (5Y Monthly)||0.17|
|PE Ratio (TTM)||20.63|
|Forward Dividend & Yield||0.91 (1.48%)|
|Ex-Dividend Date||Sep 28, 2020|
|1y Target Est||N/A|
Fujifilm Holdings Corp said on Wednesday that Shigetaka Komori, who oversaw the company's transition from film business to healthcare, would step down as chairman and chief executive in June. Komori, 81, will take a new role as chief adviser while Teiichi Goto becomes CEO and Kenji Sukeno the chairman. The transitions are subject to approval by shareholders, Fujifilm said in a release.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
A study of global trials of Fujifilm Holdings Corp's antiviral drug Avigan suggests it has little benefit for COVID-19 patients once their symptoms become serious. The meta-analysis of nine clinical trials showed the drug, known generically as favipiravir, helped patients early on in their hospitalisation, according to the preprint of a study posted Wednesday on the medical website medRxiv. "We should consider that perhaps the use of antivirals once the patient has symptoms is too late and this would explain their low efficacy in the clinical setting," wrote the authors, led by Soheil Hassanipoura of Iran's Guilan University of Medical Sciences.